Tumor-Infiltrating Lymphocytes in Patients Receiving Trastuzumab/Pertuzumab-Based Chemotherapy: A TRYPHAENA Substudy-Reference-Cited by-同舟云学术

Tumor-Infiltrating Lymphocytes in Patients Receiving Trastuzumab/Pertuzumab-Based Chemotherapy: A TRYPHAENA Substudy

Published:2018-05-18 Issue:1 Volume:111 Page:69-77
ISSN:0027-8874
Container-title:JNCI: Journal of the National Cancer Institute
language:en
Short-container-title:

Author:

Ignatiadis Michail¹²,Van den Eynden Gert³,Roberto Salgado²⁴,Fornili Marco⁵,Bareche Yacine²,Desmedt Christine²,Rothé Françoise²,Maetens Marion²,Venet David²,Holgado Esther⁶,McNally Virginia⁷,Kiermaier Astrid⁷,Savage Heidi M⁸,Wilson Timothy R⁸,Cortes Javier⁶⁹,Schneeweiss Andreas¹⁰,Willard-Gallo Karen³,Biganzoli Elia⁵,Sotiriou Christos¹²

Affiliation:

1. Department of Medical Oncology, J. C. Heuson, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium

2. Breast Cancer Translational Research Laboratory, J. C. Heuson, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium

3. Molecular Immunology Unit, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium

4. Department of Pathology, GZA, Antwerp, Belgium

5. University of Milan, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale Tumori, Milan, Italy

6. Ramon y Cajal University Hospital, Madrid, Spain

7. Oncology Biomarker Development, Genentech Inc., Basel, Switzerland

8. Oncology Biomarker Development, Genentech Inc., South San Francisco, CA

9. Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

10. Divison of Gynecologic Oncology, National Center for Tumor Diseases, University Hospital, Heidelberg, Germany

Funder

Breast Cancer Research Foundation

Fonds Nationale de la Recherche Scientifique

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

http://academic.oup.com/jnci/article-pdf/111/1/69/27441560/djy076.pdf

Reference28 articles.

1. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer;Denkert;J Clin Oncol.,2010

2. Tumor-infiltrating lymphocytes and associations with pathological complete response and event-free survival in HER2-positive early-stage breast cancer treated with lapatinib and trastuzumab: A secondary analysis of the NeoALTTO trial;Salgado;JAMA Oncol,2015

3. Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: A pooled analysis;Ignatiadis;J Clin Oncol.,2012

4. RNA sequencing to predict response to neoadjuvant anti-HER2 therapy: A secondary analysis of the NeoALTTO randomized clinical trial;Fumagalli;JAMA Oncol

5. Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial;Bianchini;Ann Oncol,2015

Cited by 54 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New Emerging Targets in Cancer Immunotherapy: The Role of B7-H3;Vaccines;2024-01-05

2. Predictive markers of treatment response to neoadjuvant systemic therapy with dual HER2-blockade;2024-01-02

3. Associations of Multiparametric Breast MRI Features, Tumor-Infiltrating Lymphocytes, and Immune Gene Signature Scores Following a Single Dose of Trastuzumab in HER2-Positive Early-Stage Breast Cancer;Cancers;2023-08-30

4. A Prognostic Model Based on Residual Cancer Burden and Tumor-Infiltrating Lymphocytes on Residual Disease after Neoadjuvant Therapy in HER2+ Breast Cancer;Clinical Cancer Research;2023-07-07

5. A scoping review of statistical methods in studies of biomarker-related treatment heterogeneity for breast cancer;BMC Medical Research Methodology;2023-06-29